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Abstract  
Fingolimod is a widely used treatment for highly active relapsing multiple sclerosis (RR MS). 
Here we report the case of a 27-year-old MS patient treated for more than two years by 
fingolimod, who presented severe hemiplegia and speech disturbances associated with 
extensive white matter lesions on brain MRI. Although initial presentation questioned the 
possibility of progressive multifocal leukoencephalopathy, final diagnosis was MS relapse 
and appropriate treatment resulted in clinical and radiological improvement. Severe MS 
relapses under fingolimod have been reported, but late onset after treatment initiation and 
extensive subcortical topography are unusual, and represent a diagnostic challenge. 
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Introduction 
Fingolimod (Gilenya
®
, Fg), the first-in-class orally compound that has shown efficacy in 
clinical trials for the treatment of relapsing-remitting multiple sclerosis (RR MS), is used as a 
first line therapy  for highly active RR MS or as a second line therapy(1). Fg is a sphingosine 
1-phosphate partial agonist that downregulates expression of S1P receptors on lymphocytes, 
preventing their recirculation from lymph nodes. Its administration results in a decrease of 
circulating T and B lymphocytes. Tumefactive MS lesions have been described under Fg, 
leading to the consideration that it may have a paradoxical effect in some cases (2). Moreover, 
5 cases of Progressive Multifocal Leukoencephalopathy (PML) have been reported in 
association with Fg, highlighting the need for cautious monitoring.  
We report the case of a 27-year-old female who presented a severe MS relapse associated 
with two atypical extensive subcortical lesions mimicking PML, occurring under Fg, 24 
months after treatment onset.  
 
Case Report  
A 27-year-old female with a 6 year-history of RR MS was admitted in our Department in July 
2015. Because of persisting clinical relapses and radiological activity under first line Disease 
Modifying Therapy, she was switched to Fg in June 2013. One month after, she reported a 
mild relapse, then remained asymptomatic (EDSS 0). In July 2015, more than two years after 
Fg onset, she developed, within a few days, a right-sided hemiplegia with severe speech 
disturbance. Brain MRI (performed 7 days after symptom-onset) revealed two new large 
subcortical white matter lesions (figure: A-H). The radiological aspect of the lesions with 
large size, irregular borders and partial involvement of U-fibers, and their occurrence under 
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Fg, were atypical for MS lesions. The presence of a strong peripheral hyperintensity on 
Diffusion Weighted Imaging (DWI), associated with an Apparent Diffusion Coefficient 
(ADC) restriction over 40%, and a faint peripheral enhancement after gadolinium injection, 
was suggestive of PML (figure: A-H). Fg was immediately stopped. Blood JC Virus (JCV) 
serology was negative (controlled twice). CSF analysis was normal; PCR for JCV in CSF was 
negative. PML was therefore excluded and the patient received IV methylprednisolone 
(IVMP) during 10 days. At day 15, brain MRI revealed an extension of the left subcortical 
white matter lesion, while ADC restriction was less visible, and areas of contrast enhancement 
had regressed (figure: I - Q). At day 21, lesions were unchanged but ADC was normalized 
(not shown). In August 2015, she had a new relapse with a cerebellar ataxia, right-sided facial 
hypoesthesia and left-sided hypoesthesia. EDSS was of 6.0. Brain MRI showed a new 
extensive lesion of the right middle cerebellar peduncle (not shown); the previous lesions 
were unchanged. She received IVMP and natalizumab (Nz) was initiated in October 2015. 
She progressively clinically improved, with an EDSS of 3.0 after 6 months of Nz treatment. 
Follow-up MRI showed a complete regression of DWI hyperintensities and the absence of 
contrast enhancement (figure: R - W).  
 
Discussion 
This case shows the complexity to reach a diagnosis in the case of extensive encephalic 
lesions appearing 2 years after Fg initiation. 
Given the severity of the neurological symptoms (hemiplegia and speech disturbance) and the 
radiological aspect of the lesions (large size, irregular borders, involvement of some U-fibers, 
peripheral DWI hyperintensity with ADC restriction and marginal contrast enhancement (3)), 
PML was the first hypothesized diagnosis. Even if few PML cases have been described with 
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Fg, prescription and follow-up guidelines do not include JCV serology, and the unknown 
status of our patient at first reinforced the suspicion for this diagnosis. PML was finally ruled 
out by the negativity of JCV serology and the JCV-PCR in the CSF. However, these viral 
results are not immediately available; in addition, a recent PML case has been diagnosed in an 
MS patient despite a negative JCV serology 2 weeks after the onset of symptoms (5). 
Concerning ADC, which is known to be reduced in PML lesions, decrease (up to 66%) in the 
very early phase of acute MS lesions has been documented, especially in the first 7 days (with 
a maximum of 10 days) after symptom onset (4). This radiological finding is thus not 
completely specific of PML. 
Severe MS relapses under Fg have been reported in particular situations: i) during a switch 
between natalizumab to Fg (6), ii) after Fg cessation, as a rebound effect (7), and iii) during 
the first 5 months of treatment, which can be equivalent to a lack of efficacy or even questions 
a paradoxical effect (2, 8). Hellman et al (9) reported a case of tumefactive demyelination, 
beginning 14 months after Fg treatment onset, with a diagnosis of typical demyelination on 
brain biopsy performed 22 months after Fg initiation. Our case is, to our knowledge, the first 
report of extensive subcortical lesions after 24 months of well-conducted treatment with Fg. 
The long clinical and radiological stability before a spectacular aggressive activity of MS 
disease questions the physiopathology of such disease “rebound”. Although mechanisms 
involved in such aggressive MS relapses are unknown, the presence of neutralizing antibodies 
against Fg, in analogy with those described against natalizumab(10) might be hypothesized.  
Cautious monitoring is needed for MS patients with Fg, even after 2 years of well-conducted 
and well-tolerated treatment. This case also emphasizes the relevance of a precise description 
of such extensive subcortical lesions and their evolution in order to differentiate MS relapse 
from PML, hence optimize therapeutic strategy.  
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Legend 
Brain MRI:   
Brain MRI performed at day 7 (A-H); day 15 (I-Q) and at month 7 (R-W) of symptoms onset 
(D0).  
From left to right column: Fluid-Attenuated Inversion Recovery sequences (A, E, I, N, R, U), 
T1 sequences with contrast (B, F, K, O, S, V), Diffusion-Weighted sequences (C, G, L, P, T, 
W), and Apparent Diffusion Coefficient maps (D, H, M, Q).  
MRI at D7 shows extensive lesion of left frontoparietal and right parietal white matter, 
hyperintense on FLAIR with punctate, irregular margins (A&E), midly hypointense on T1 
with a faint peripheral enhancement (B&F,yellow arrows), a strong hyperintensity on DWI 
(C&G) and an ADC decrease over 40% (D&H,red arrows). Subcortical U-fibers are partially 
involved. MRI at D15 shows extension of FLAIR and DWI hyperintensity but regression of 
contrast enhancement (K&O) and partial regression of ADC restriction (M&Q). MRI at M7 
shows complete regression of DWI high signal and no contrast enhancement. 
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